Dolutegravir shows promise in pregnancy
Study comparing commonly used antiretroviral regimens in pregnancy reports viral suppression at delivery in considerably more participants taking dolutegravir.
List view / Grid view
Study comparing commonly used antiretroviral regimens in pregnancy reports viral suppression at delivery in considerably more participants taking dolutegravir.
Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in the Melody Phase III trial.
Over 90 percent of β-thalassemia patients treated with Betibeglogene autotemcel (beti-cel) achieved transfusion independence lasting over a year.